IROP
IRREGULARITY ON NOTICE OF POSSIBLE OPPOSITION RECEIVED FROM IB
28/07/2026
Voltar para busca
Dado oficial do USPTO
CONFOGEN
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Snapshot rápido
CONFOGEN
ST13
US500000079404957Classe
1, 5, 35, 42
Pedido
79404957
Registro
7877158
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
31
Atualização mais recente
28/07/2026
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
1, 5, 35, 42
Data de depósito
09/07/2024
Data de registro
05/08/2025
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
05/08/2025
Última transação
28/07/2026
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Código do desenho
4
Tipo de titular
32
Localização do titular
B-9052 Zwijnaarde, BE
Examinador
SWEENEY, MOLLY B
Unidade examinadora
N30
Localização atual
FILE REPOSITORY (FRANCONIA)
Titulares e representantes
Titulares
Confo Therapeutics NV
Confo Therapeutics N.V.
Representantes
Jessica S. Sachs Harness, Dickey & Pierce, P.L.C.
Classificação técnica
Classes Nice
Classe 1Classe 5Classe 35Classe 42
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 1
Laboratory chemicals for scientific use; biochemicals for in vitro and in vivo scientific use; biochemical substancesantibodies for stabilization of proteinsall the aforementioned substances for scientific use and for use in laboratories; reagents for medical research; diagnostic preparations for scientific or research use; chemical reagents for use in genetic research; receptors and reagents for testing for G protein-coupled receptors (GPCRs); chemical substances for use in the production of drugs; biochemical and chemical substances and chemical reagents for measuring combined or divided natural and non-natural G protein-coupled receptors (GPCRs); proteins for use in science; chimeric proteins to measuretest and develop compounds and ligands binding to G protein-coupled receptors (GPCRs).
Classe 5
Pharmaceutical and veterinary preparations for use in oncology and immunology and for inflammatoryinfectiongastro-intestinalcardiovascularpulmonaryneurologicalmetabolicsystemicgynecologicalurologicaldermatologicalmusculo-skeletal treatment and treatment of orphan diseases; chemical and biochemical substances for pharmaceutical or veterinary use screened by means of stabilized proteinssmall molecules and antibodies for use in oncology and immunology and for inflammatoryinfectiongastro-intestinalcardiovascularpulmonaryneurologicalmetabolicsystemicgynecologicalurologicaldermatologicalmusculo-skeletal treatment and treatment of orphan diseases; veterinary productsantigens and reagents for use in oncology and immunology and for inflammatoryinfectiongastro-intestinalcardiovascularpulmonaryneurologicalmetabolicsystemicgynecologicalurologicaldermatologicalmusculo-skeletal treatment and treatment of orphan diseases
Classe 35
Collating of data in computer databases; computerized file management; data processing; automated processing of medical and pharmaceutical data; compilation of statistical data relating to medical research and development; computer database management.
Classe 42
Medical and pharmacological research services; pharmaceutical drug development services; laboratory research services relating to pharmaceuticals; research and development of vaccines and medicines; scientific research for medical purposes and the development of pharmaceutical preparations in the area of drugs interacting with g protein-coupled receptors (GPCRs); design of computer databases; updating of database software; data warehousing; provision of information and data relating to medical research and development; rendering of computer graphics featuring digital image correction for research and development; computer graphic design services featuring data and image processing services for making three dimensional models; non-medical graphic design featuring digital imaging services; optical imaging for use in research and development of medicines; imaging via computers for use in research and development of medicines; graphic design services for generating and processing data and images for making three dimensional models for use in research and development of medicines.
Publicações
Histórico de despachos e eventos da marca no USPTO.
31 publicações encontradas
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
13/07/2026
OPNR
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
12/07/2026
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
05/03/2026
FICS
FINAL DISPOSITION NOTICE SENT TO IB
15/02/2026
FIMP
FINAL DISPOSITION PROCESSED
15/02/2026
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
05/11/2025
CORR
CORRECTION FROM IB ENTERED - NO REVIEW REQUIRED
12/08/2025
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
05/08/2025
R.PR
REGISTERED-PRINCIPAL REGISTER
05/08/2025
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
17/06/2025
PUBO
PUBLISHED FOR OPPOSITION
17/06/2025
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
11/06/2025
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
14/05/2025
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
12/05/2025
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
12/05/2025
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
12/05/2025
RFNT
REFUSAL PROCESSED BY IB
05/04/2025
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
16/03/2025
RFRR
REFUSAL PROCESSED BY MPU
15/03/2025
CRCV
CORRECTION TRANSACTION RECEIVED FROM IB
14/02/2025
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
07/02/2025
CNRT
NON-FINAL ACTION WRITTEN
06/02/2025
RFWR
NON-FINAL ACTION (IB REFUSAL) WITHDRAWN FOR REVIEW
06/02/2025
ADCH
CHANGE OF NAME/ADDRESS REC'D FROM IB
31/01/2025
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
01/01/2025
CNRT
NON-FINAL ACTION WRITTEN
31/12/2024
DOCK
ASSIGNED TO EXAMINER
30/12/2024
MAFR
APPLICATION FILING RECEIPT MAILED
27/09/2024
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
27/09/2024
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
26/09/2024
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace CONFOGEN ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.